Tokyo, July 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058598) titled 'Regulatory mechanism of adrenal hormone secretion by establishment of cell lines derived from adrenal tumors' on July 25.
Study Type:
Observational
Primary Sponsor:
Institute - Wakayama Medical University
Condition:
Condition - Functional adrenal tumor
Classification by malignancy - Others
Genomic information - YES
Objective:
Narrative objectives1 - Establish a research platform for functional adrenal tumors.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 16
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients with adrenal tumor on imaging studies and abnormal adrenal hormone secretion on endocrine function tests
Key exclusion criteria - Patients with no adrenal tumor on imaging studies or no abnormal adrenal hormone secretion on endocrine function tests
Patients who did not give consent for clinical research
Target Size - 15
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2022 Year 01 Month 21 Day
Date of IRB - 2022 Year 01 Month 21 Day
Anticipated trial start date - 2022 Year 01 Month 21 Day
Last follow-up date - 2027 Year 01 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067003
Disclaimer: Curated by HT Syndication.
